A Phase 3 interventional study of Linagliptin and Linagliptin in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 43 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-03-28.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 8 that started in 2010, is one of 31 in phase 3, and was the 21st registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Bahria University · Sites in Pakistan
Ages 30–55
By country, each count listing its studies:
Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 8 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 574 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 175 across the 67 interventional studies. Of the 60 that completed or were terminated, 41 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 67 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 31st largest by enrollment of the 96 interventional ones that give a count, is one of 18 that started in 2010, is one of 50 in phase 3, and was the 41st registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The objective of the current study is to investigate the safety and efficacy of linagliptin (5mg / once daily) given for 52 weeks as add-on therapy to patients with type 2 diabetes mellitus and insufficient glycaemic control despite diet, exercise, and treatment with one approved antidiabetic drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
biguanide plus linagliptin
Drug: Linagliptin
glinide plus linagliptin
Drug: Linagliptin
glitazone plus linagliptin
Drug: Linagliptin
sulfonylurea plus linagliptin
Drug: Linagliptin
alpha-glucosidase inhibitor plus linagliptin
Drug: Linagliptin
sulfonylurea plus metformin
Drug: Metformin
alpha-glucosidase inhibitor plus metformin
Drug: Metformin
Linagliptin once daily
Linagliptin once daily
Metformin twice or three time per day
Metformin twice or three time per day
Linagliptin once daily
Linagliptin once daily
Linagliptin once daily
Incidence of Adverse Events (AEs)
The number of patient with any AEs, patients with severe AE, patients with AEs leading to discontinuation of trial drug, and patients with Hypoglycaemic events
Time frame: The first drug administration through 7 days after the last drug administration, up to 382 days
Glycosylated Haemoglobin A1c (HbA1c)
The change from baseline in HbA1c after 52 weeks of treatment. When the HbA1c after 52 weeks treatment was missing, the value from the measurements at the closest preceding visit replaced the missing value.
Time frame: Baseline and 52 weeks
A total of 618 patients were enrolled in the trial at 43 trial sites, and 37 patients were withdrawn from the trial because of screening failure. 581 patients were entered into the 2-week placebo run-in period, and 7 patients were withdrawn. 574 patients completed the 2-week placebo run-in period and took linagliptin 5 mg or metformin.
| Milestone | Bigu+Lina | Glin+Lina | Glit+Lina | SU+Lina | A-GI+Lina | SU+Met | A-GI+Met |
|---|---|---|---|---|---|---|---|
| Started | 82 | 66 | 74 | 143 | 85 | 63 | 61 |
| Completed | 79 | 58 | 69 | 132 | 83 | 58 | 59 |
| Not completed | 3 | 8 | 5 | 11 | 2 | 5 | 2 |
| Withdrew: Adverse event | 2 | 6 | 0 | 7 | 1 | 4 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 2 | 1 | 1 | 1 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Other (house moving) | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
The number of patient with any AEs, patients with severe AE, patients with AEs leading to discontinuation of trial drug, and patients with Hypoglycaemic events
| Patients | Bigu+Lina | Glin+Lina | Glit+Lina | SU+Lina | A-GI+Lina | SU+Met | A-GI+Met |
|---|---|---|---|---|---|---|---|
| Patients with any AE | 69 | 55 | 62 | 114 | 71 | 44 | 52 |
| Patients with severe AE | 1 | 1 | 0 | 2 | 1 | 1 | 0 |
| Patients with AEs leading to discontinuation | 2 | 5 | 0 | 8 | 1 | 4 | 0 |
| Patients with Hypoglycaemic events | 1 | 0 | 2 | 21 | 2 | 10 | 2 |
The change from baseline in HbA1c after 52 weeks of treatment. When the HbA1c after 52 weeks treatment was missing, the value from the measurements at the closest preceding visit replaced the missing value.
| Percentage | Bigu+Lina | Glin+Lina | Glit+Lina | SU+Lina | A-GI+Lina | SU+Met | A-GI+Met |
|---|---|---|---|---|---|---|---|
| Baseline | 7.98 ± 0.75 | 7.92 ± 0.82 | 7.86 ± 0.83 | 8.12 ± 0.78 | 7.87 ± 0.75 | 8.01 ± 0.64 | 8.07 ± 1.04 |
| At 52 weeks | 7.10 ± 0.82 | 7.19 ± 0.75 | 7.07 ± 0.74 | 7.42 ± 0.91 | 6.96 ± 0.75 | 7.19 ± 0.72 | 6.98 ± 0.75 |
| Change from baseline to 52 weeks | -0.88 ± 0.64 | -0.73 ± 0.65 | -0.79 ± 0.50 | -0.70 ± 0.70 | -0.91 ± 0.61 | -0.82 ± 0.78 | -1.09 ± 0.87 |
Collected over The first drug administration through 7 days after the last drug administration, up to 382 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bigu+Lina | — | 8/82 (9.8%) | 55/82 (67.1%) |
| Glin+Lina | — | 5/66 (7.6%) | 41/66 (62.1%) |
| Glit+Lina | — | 2/74 (2.7%) | 37/74 (50%) |
| SU+Lina | — | 7/143 (4.9%) | 83/143 (58%) |
| A-GI+Lina | — | 7/85 (8.2%) | 54/85 (63.5%) |
| SU+Met | — | 5/63 (7.9%) | 31/63 (49.2%) |
| A-GI+Met | — | 3/61 (4.9%) | 33/61 (54.1%) |
| Event | Bigu+Lina | Glin+Lina | Glit+Lina | SU+Lina | A-GI+Lina | SU+Met | A-GI+Met |
|---|---|---|---|---|---|---|---|
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/82 | 0/66 | 0/74 | 0/143 | 2/85 | 0/63 | 0/61 |
| PneumoniaInfections and infestations | 0/82 | 0/66 | 0/74 | 0/143 | 1/85 | 0/63 | 1/61 |
| CataractEye disorders | 0/82 | 0/66 | 0/74 | 1/143 | 0/85 | 0/63 | 1/61 |
| Vertigo positionalEar and labyrinth disorders | 0/82 | 0/66 | 0/74 | 0/143 | 0/85 | 0/63 | 1/61 |
| Gastroenteritis viralInfections and infestations | 0/82 | 0/66 | 0/74 | 0/143 | 0/85 | 1/63 | 0/61 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/82 | 0/66 | 0/74 | 0/143 | 0/85 | 1/63 | 0/61 |
| Cerebral infarctionNervous system disorders | 1/82 | 0/66 | 0/74 | 0/143 | 0/85 | 1/63 | 0/61 |
| Cholecystitis acuteHepatobiliary disorders | 0/82 | 0/66 | 0/74 | 0/143 | 0/85 | 1/63 | 0/61 |
| CholelithiasisHepatobiliary disorders | 0/82 | 0/66 | 0/74 | 0/143 | 0/85 | 1/63 | 0/61 |
| Thermal burnInjury, poisoning and procedural complications | 0/82 | 0/66 | 0/74 | 0/143 | 0/85 | 1/63 | 0/61 |
| Event | Bigu+Lina | Glin+Lina | Glit+Lina | SU+Lina | A-GI+Lina | SU+Met | A-GI+Met |
|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 30/82 | 30/66 | 25/74 | 45/143 | 35/85 | 13/63 | 27/61 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/82 | 0/66 | 2/74 | 20/143 | 1/85 | 10/63 | 2/61 |
| BronchitisInfections and infestations | 9/82 | 1/66 | 1/74 | 5/143 | 3/85 | 1/63 | 3/61 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 4/82 | 2/66 | 6/74 | 4/143 | 3/85 | 0/63 | 6/61 |
| ContusionInjury, poisoning and procedural complications | 4/82 | 2/66 | 1/74 | 10/143 | 2/85 | 1/63 | 5/61 |
| PharyngitisInfections and infestations | 5/82 | 5/66 | 3/74 | 5/143 | 2/85 | 2/63 | 0/61 |
| FallInjury, poisoning and procedural complications | 4/82 | 3/66 | 1/74 | 10/143 | 3/85 | 1/63 | 4/61 |
| GastroenteritisInfections and infestations | 2/82 | 1/66 | 2/74 | 4/143 | 4/85 | 4/63 | 1/61 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/82 | 0/66 | 1/74 | 0/143 | 1/85 | 4/63 | 0/61 |
| ConstipationGastrointestinal disorders | 3/82 | 3/66 | 2/74 | 4/143 | 5/85 | 4/63 | 1/61 |
| Age, Customized(years) | Bigu+Lina | Glin+Lina | Glit+Lina | SU+Lina | A-GI+Lina | SU+Met | A-GI+Met | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 58.4 ± 9.9 | 62.6 ± 8.8 | 60.4 ± 9.4 | 61.8 ± 10.8 | 62.0 ± 10.4 | 61.2 ± 10.6 | 59.3 ± 10.3 | 60.9 ± 10.2 |
| Sex: Female, Male(Participants) | Bigu+Lina | Glin+Lina | Glit+Lina | SU+Lina | A-GI+Lina | SU+Met | A-GI+Met | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 33 | 18 | 16 | 38 | 30 | 19 | 19 | 173 |
| Male | 49 | 48 | 58 | 105 | 55 | 44 | 42 | 401 |
The record gives a start of Sep 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linagliptin